CareDx Announces the Success of Its Tender Offer for Allenex

CareDx, Inc.’s (NASDAQ:CDNA) offer to the shareholders of Allenex AB (publ) has been accepted by shareholders holding an aggregate of 118,207,862 shares, corresponding to approximately 98.3% of the total number of shares in Allenex. CareDx declares the offer unconditional and completes the offer.  The settlement is expected to occur on or around April 13, 2016.
According to the news:

On December 16, 2015, CareDx, Inc. announced a recommended public offer to the shareholders of Allenex to tender all their shares in Allenex to CareDx. On February 9, 2016, CareDx announced that the common stock component of the share based consideration alternatives had been revised. An offer document regarding the Offer was made public on March 7, 2016 and the acceptance period commenced on March 8, 2016. On March 29, 2016, the acceptance period was extended by five days to April 5, 2016 and on March 30, 2016, CareDx published a supplement to the Offer Document, whereby Allenex shareholders were, in accordance with Nasdaq Stockholm’s takeover rules, given the right to withdraw submitted acceptances by April 6, 2016.

Peter Maag, President and Chief Executive Officer of CareDx stated:

We at CareDx are pleased with the high acceptance by Allenex shareholders. The combination of our 2 organizations creates a unique diagnostics company that focuses on patient outcomes along the pre-to-post transplant continuum.

Click here to view the full press release.